Similarly, drug repurposing strategies have identified existing medications, including GLP-1 receptor agonists and PPAR agonists, as potential treatments for MASH by leveraging their known mechanisms of action and safety profiles [53,54]. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.